Apopulation-based cytogenetic study of adults with acute lymphoblastic leukemia

Blood

Volumn 115, Issue 2, 2010, Pages 206-214

  Moorman, Anthony V ^a   Chilton, Lucy ^a   Wilkinson, Jennifer ^b   Ensor, Hannah M ^a   Bown, Nick ^c   Proctor, Stephen J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; GENE TRANSLOCATION; GENETICS; HUMAN CHROMOSOME; INCIDENCE; METABOLISM; MIDDLE AGED; MORTALITY; PLOIDY; PROGNOSIS; SURVIVAL RATE; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; CHROMOSOMES, HUMAN; ENGLAND; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLOIDIES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 75649092322     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-232124     Document Type: Article

References (31)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15): 1535-1548.
2. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/ Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-3197.
3. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563-2572.
4. Feltbower RG, McNally RJ, Kinsey SE, et al. Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002. Eur J Cancer. 2009;45(3): 420-427.
5. Taylor PR, Reid MM, Bown N, Hamilton PJ, Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: a populationbased study of incidence and outcome. Blood. 1992;80(7):1813-1817.
6. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408-1411.
7. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032-2035.
8. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48(3):254-261.
9. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774-780.
10. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? a comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112(5):1646-1654.
11. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144(2):147-156.
12. Goekbuget N, Leguay T, Hunault M, et al. First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation [abstract]. Blood. 2008; 112(11):304.
13. Shaffer LG, Tommerup M, eds. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 2005.
14. Proctor SJ, Hamilton PJ, Taylor P, et al. A comparative study of combination chemotherapy versus marrow transplant in first remission in adult acute lymphoblastic leukaemia. Br J Haematol. 1988;69(1):35-39.
15. Proctor SJ, Taylor P, Thompson RB, et al. Acute lymphoblastic leukaemia in adults in the northern region of England - a study of 75 cases. Q J Med. 1985;57(223):761-774.
16. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111(4):1827-1833.
17. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol. 1997;96(3):601-610.
18. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL); an MRC UKALL12/ ECOG 2993 study. Blood. 2007;109(3):944-950.
19. Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel E. Patients' age and BCRABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112(3):918-919.
20. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105(9):3434-3441.
21. GFCH. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique. Blood. 1996;87(8):3135-3142.
22. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93(11):3983-3993.
23. McNally RJQ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol. 1997; 15(4):173-189.
24. Stiller CA, Benjamin S, Cartwright RA, et al. Patterns of care and survival for adolescents and young adults with acute leukaemia - a population-based study. Br J Cancer. 1999;79(3-4):658-665.
25. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer. 1991;3(1):1-7.
26. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-764.
27. Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-114.
28. Paulsson K, Cazier JB, Macdougall F, et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A. 2008;105(18):6708-6713.
29. Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144(4):468-483.
30. Jabbar Al-Obaidi MS, Martineau M, et al. ETV6/ AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia. 2002;16(4):669-674.
31. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-1580.